Gelteq (GELS) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Gelteq is the larger company by market cap ($3.1 million vs $3.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GELS | SKYE |
|---|---|---|
| Share price | $0.2701 | $0.70 |
| Market cap | $3.11M | $3.10M |
| 1-day change | -3.74% | -11.03% |
| EPS (TTM) | $-0.44 | $-7.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-6.65M | $-55.92M |
| 52-week high | $2.01 | $11.04 |
| 52-week low | $0.255 | $0.484 |
| Distance from 52-week high | -86.56% | -93.66% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +9614.29% |
| Average volume | 2.85M | 88.19K |
| Shares outstanding | 11.51M | 4.42M |
| Employees | 7 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Gelteq
GELS stock →Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
GELS vs SKYE FAQ
Which is bigger, Gelteq or Skye Bioscience?
Gelteq (GELS) is larger, with a market capitalization of $3.11M compared with $3.10M for Skye Bioscience (SKYE).
Are Gelteq and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.